Daraxonrasib Reaches Pancreatic Cancer Patients After 13.2-Month Survival Result
Updated
Updated · Yahoo! Voices · Aug 23
Daraxonrasib Reaches Pancreatic Cancer Patients After 13.2-Month Survival Result
3 articles · Updated · Yahoo! Voices · Aug 23
Summary
Expanded-access supplies of daraxonrasib are now reaching metastatic pancreatic cancer patients before FDA approval, with a South Carolina patient among the first to start the experimental pill.
Phase 3 data presented this summer showed median survival of 13.2 months versus 6.6 months on standard chemotherapy, a rare gain in a cancer where advanced cases often kill within a year.
Doctors say the drug's importance lies in hitting KRAS, the mutation driving more than 90% of pancreatic cancers and one that had resisted targeted therapies.
Access remains limited and the treatment can be harsh, with mouth sores, severe sore throat and rash reported even as more patients ask for the drug.
The early rollout could reshape care beyond late-stage disease if future trials show the drug can shrink tumors before surgery or reduce recurrence afterward.
Could a once-undruggable mutation hold the key to doubling pancreatic cancer survival, and who gets access first?
As an experimental drug doubles survival rates, will its severe side effects overshadow the rare hope it offers?
Daraxonrasib Doubles Survival in Metastatic Pancreatic Cancer: Landmark RASolute 302 Phase 3 Results and the Rise of RAS(ON) Inhibition
Overview
In June 2026, the Phase 3 RASolute 302 trial revealed that daraxonrasib, an oral, once-daily RAS inhibitor, dramatically reduced the risk of death and doubled survival for patients with metastatic pancreatic cancer compared to chemotherapy. This breakthrough was achieved through a unique 'molecular glue' mechanism that blocks active RAS signaling, delivering consistent benefits across different genetic mutations. Daraxonrasib also preserved quality of life and had fewer severe side effects, leading to rapid regulatory progress, including FDA review and an Expanded Access Program reaching thousands of patients. Encouraging early results in first-line treatment are now being tested in a global Phase 3 trial.